Muhammad Sabry Mazroua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Sabry Mazroua has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Nathan L. Liang
University of Pittsburgh Medical Center, Division of Vascular Surgery, Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
2 shared publications - Aditi S. Kothari
Global Remote Research Scholars Program, St. Paul, Minnesota, US; BJ Medical College, Ahmedabad
1 shared publication - Ahmed E. Ali
Department of Internal Medicine, Crestwood Medical Center, Huntsville, AL 35801, USA
1 shared publication - Amanda R. Phillips
Division of Vascular Surgery, Temple University School of Medicine, Philadelphia, PA, USA
1 shared publication Edith Tzeng
Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication- Joanna Lee
Department of Medicine, St Mary Medical Center, Langhorne, PA 19047, USA
1 shared publication
Latest Publications
- Open Access
- 19 December 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 889-890
Radiation Reduction Strategies for Endovascular Repair of Complex Aortic Aneurysms
- 19 December 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 889-890
Open AccessRadiation Reduction Strategies for Endovascular Repair of Complex Aortic Aneurysms
- Open Access
- 18 February 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (6) , 824-834
External Validation of Eight Ruptured Abdominal Aortic Aneurysm Mortality Prediction Models Demonstrates Limited Predictive Accuracy
- 18 February 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (6) , 824-834
Open AccessExternal Validation of Eight Ruptured Abdominal Aortic Aneurysm Mortality Prediction Models Demonstrates Limited Predictive Accuracy
- Open Access
- 23 January 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1) , 45
Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Background: Heart failure (HF) is a major cause of recurrent hospitalization and death worldwide. Sodium-glucose cotransporter-2 inhibitors including Dapagliflozin are anti-diabetic drugs with promising cardiovascular (CV) effects. We performed systematic review and meta-analysis of randomized controlled trials investigating the effects of Dapagliflozin in heart failure patients. Methods: We searched PubMed, Scopus and ScienceDirect databases. A total of 1,567 studies from January 2017 to September 10, 2022, were screened. After applying exclusion criteria, 22 studies were retrieved for full-text screening, and 9 of them were eligible for this meta-analysis. Effect estimates for dichotomous variables were expressed as risk ratio (RR) and 95% CI. The primary outcomes were the incidence of all-cause mortality, hospitalization due to HF and CV death. This review was registered on PROSPERO with ID CRD42022347793. Results: A total of 14,032 patients were included. The overall risk ratio of all-cause mortality favored the dapagliflozin group over the placebo/standard therapy group (RR= 0.89, 95% CI: 0.82 - 0.97, P=0.006) and the pooled studies were not heterogenous (I2= 0%). Additionally, Dapagliflozin significantly reduced the hospitalization due to heart failure (RR= 0.76, 95% CI: 0.70 – 0.84, P> 0.00001, I2= 0%), cardiovascular death (RR= 0.87, 95% CI: 0.78 – 0.97, P= 0.01, I2= 0%) and their composite outcomes. Conclusion: Dapagliflozin reduces the risk of all-cause mortality, heart failure hospitalizations and cardiovascular death in a wide range of heart failure patients.
- 23 January 2023
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 18 (1) , 45
Open AccessEffect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Background: Heart failure (HF) is a major cause of recurrent hospitalization and death worldwide. Sodium-glucose cotransporter-2 inhibitors including Dapagliflozin are anti-diabetic drugs with promising cardiovascular (CV) effects. We performed systematic review and meta-analysis of randomized controlled trials investigating the effects of Dapagliflozin in heart failure patients. Methods: We searched PubMed, Scopus and ScienceDirect databases. A total of 1,567 studies from January 2017 to September 10, 2022, were screened. After applying exclusion criteria, 22 studies were retrieved for full-text screening, and 9 of them were eligible for this meta-analysis. Effect estimates for dichotomous variables were expressed as risk ratio (RR) and 95% CI. The primary outcomes were the incidence of all-cause mortality, hospitalization due to HF and CV death. This review was registered on PROSPERO with ID CRD42022347793. Results: A total of 14,032 patients were included. The overall risk ratio of all-cause mortality favored the dapagliflozin group over the placebo/standard therapy group (RR= 0.89, 95% CI: 0.82 - 0.97, P=0.006) and the pooled studies were not heterogenous (I2= 0%). Additionally, Dapagliflozin significantly reduced the hospitalization due to heart failure (RR= 0.76, 95% CI: 0.70 – 0.84, P> 0.00001, I2= 0%), cardiovascular death (RR= 0.87, 95% CI: 0.78 – 0.97, P= 0.01, I2= 0%) and their composite outcomes. Conclusion: Dapagliflozin reduces the risk of all-cause mortality, heart failure hospitalizations and cardiovascular death in a wide range of heart failure patients.